Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines. 2011

Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
James Graham Brown Cancer Center, 529 South Jackson Street, University of Louisville, Louisville, KY 40202, U.S.A.

The National Cancer Institute's Developmental Therapeutics Program (DTP) maintains the screening results obtained in 60 standardized cancer cell lines for ~43,000 compounds. Here the application of the categorical structure-activity relationship (cat-SAR) program for the identification of the structural attributes of identified compounds that display differential cytostatic or cytotoxic activity to one breast cancer cell line and not another is reported. The goal of this approach is to separate features associated with antiproliferative activity towards many cell lines from those that affect only a specific cell type. To assess this approach, SAR models were developed for cytostatic and cytotoxic activity against the human breast cancer cell lines MCF-7 and MDAMB-231 and three differential activity models for compounds that were potent cytostatic and cytotoxic agents in MCF-7 cells, but relatively inactive against MDA-MB-231 cells. The MCF-7 and MDA-MB-231 models comprised the most potent 200 active and least potent 200 inactive compounds found in the DTP database and the differential activity models comprised 200 compounds potent in one cell line and not the other and 200 compounds equally potent between the cell lines. Leave-one-out validations of the individual MCF-7 and MDA-MB-231 models returned values between 83 and 85% concordance, with values obtained between 66 and 76% concordance for the differential activity models. The cat-SAR approach identified the chemical attributes associated with cytostatic and cytotoxic activity for the MCF-7 and MDA-MB-231 breast cancer cell lines included in the DTP and furthermore, were able to differentiate the selective activity of compounds between the two breast cancer lines. Thus it is conceivable that such cell line-specific mechanisms could be exploited for the discovery of highly specific anti-breast cancer agents and could also potentially facilitate the development of SAR models with sufficient resolution and clarity to identify chemical moieties associated with antiproliferative activity towards selective individual cancer types while being innocuous to other cell types.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
February 2012, Asian Pacific journal of tropical biomedicine,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
March 1998, Breast cancer research and treatment,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
January 2008, Planta medica,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
February 2021, Asian Pacific journal of cancer prevention : APJCP,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
September 2003, Ginekologia polska,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
May 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
October 2021, Current molecular pharmacology,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
November 2023, Heliyon,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
August 2023, 3 Biotech,
Shahid Qamar, and C Alex Carrasquer, and Suzanne L Cunningham, and Albert R Cunningham
August 2002, Molecular carcinogenesis,
Copied contents to your clipboard!